IRulya Therapeutics Inc. (IRLA)
NASDAQ: IRLA · Real-Time Price · USD
32.95
+1.33 (4.21%)
At close: Oct 30, 2026, 4:00 PM EDT
33.50
+0.55 (1.67%)
After-hours: Oct 30, 2026, 7:30 PM EDT
IRulya Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, IRulya Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $75. The average 1-year stock price forecast is 127.62% higher than the current stock price, while the lowest is $65 (+97.27%) and the highest is $98 (+197.42%).
Price Target: $75 (+127.62%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for IRulya Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 3 | 4 | 5 | 6 | 6 |
| Buy | 0 | 0 | 0 | 0 | 1 | 2 |
| Hold | 3 | 3 | 2 | 2 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 6 | 6 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Buy Initiates $72 | Buy | Initiates | $72 | +118.51% | Oct 9, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $98 | Buy | Maintains | $98 | +197.42% | Sep 30, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates $68 | Buy | Reiterates | $68 | +106.37% | Sep 30, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains $68 | Buy | Maintains | $68 | +106.37% | Sep 30, 2026 |
| Rodman & Renshaw | Rodman & Renshaw | Buy Initiates $70 | Buy | Initiates | $70 | +112.44% | Sep 24, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.65
from -336.00
EPS Next Year
-4.68
from -3.65
EPS and Forward PE are based on non-GAAP adjusted numbers.